Evidence map›Paper›PMID 35557587›Full record

ArticleJournal of gastrointestinal oncology2022

Biliary cancer brain metastases: a multi-institution case series with case reports.

Samuel R Falkson, Karen Zhang, Hriday P Bhambhvani, Jennifer L Wild, Ann Griffin, Robin K Kelley, Melanie Hayden Gephart

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel R Falkson *Department of Neurosurgery, Stanford University Medical Center, Stanford, CA, USA.
Karen Zhang *UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Hriday P BhambhvaniDepartment of Neurosurgery, Stanford University Medical Center, Stanford, CA, USA.
Jennifer L WildUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Ann GriffinUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Robin K KelleyUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University Medical Center, Stanford, CA, USA.

Funding

TOOLKIT CoreU54CA261717 · NCI · STANFORD UNIVERSITY · PI Melanie Hayden Gephart · 2021 to 2026
$8.9M
Tumor DNA in CSF and novel modeling decode breast cancer - brain metastasesK08NS091527 · NINDS · STANFORD UNIVERSITY · PI HAYDEN GEPHART, MELANIE · 2016 to 2020
$928k
NCI NIH HHS U54 CA261717NINDS NIH HHS K08 NS091527
6 · The paper itself

Abstract

Background: Biliary cancers are rare, and few reported cases of brain metastases from primary biliary cancers exist, especially describing patients in the United States. This report assesses the proportion and incidence of brain metastases arising from primary biliary cancers [cholangiocarcinoma (CCA) and gallbladder cancer] at Stanford University and the University of California, San Francisco, describes clinical characteristics, and provides a case series. Methods: We queried 3 clinical databases at Stanford and the University of California, San Francisco to retrospectively identify and review the charts of 15 patients with brain metastases from primary biliary cancers occurring between 1990 to 2020. Results: Among patients with brain metastases analyzed at Stanford (3,585), 6 had a primary biliary cancer, representing 0.17% of all brain metastases. Among biliary cancer patients at the University of California, San Francisco (1,055), 9 had brain metastases, representing an incidence in biliary cancer of 0.85%. A total of 15 biliary cancer patients with brain metastases were identified at the two institutions. Thirteen out of 15 patients (86.7%, 95% CI: 59.5-98.3) were female. The median overall survival from primary biliary cancer diagnosis was 214 days (95% CI: 71.69-336.82 days) and subsequent OS from the time of brain metastasis diagnosis was 57 days (95% CI: 13.43-120.64 days). Death within 90 days of brain metastasis diagnosis occurred in 66.67% of patients (95% CI: 38.38-88.17). Conclusions: Brain metastases from primary biliary cancers are rare, with limited survival once diagnosed. This report can aid health care providers in caring for patients with brain metastases from primary biliary cancers.

Indexed as

biliary cancersBrain metastasescholangiocarcinoma (CCA)gallbladder adenocarcinoma (GBA)gallbladder cancer

Identifiers

PMID35557587
PMCPMC9086048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.